{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T03:15:06Z","timestamp":1791256506344,"version":"4.1.0"},"reference-count":315,"publisher":"MDPI AG","issue":"18","license":[{"start":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T00:00:00Z","timestamp":1757462400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Pharmaceutical companies keep producing novel drugs and drug treatments for improving the life of every sick individual, most often following a pattern; a specific drug for a specific condition. Evidence suggests that different medications can have a positive effect on different pathological conditions. The full potential of existing therapies can be revealed through drug repurposing\u2014also referred to as drug repositioning, reprofiling, or re-tasking\u2014which involves identifying new therapeutic uses for approved or investigational drugs beyond their original indications. One significant target in this context is the renin\u2013angiotensin\u2013aldosterone system (RAAS), a crucial regulator of blood pressure and fluid homeostasis, and a central focus in the treatment of chronic cardiovascular conditions such as arterial hypertension (AH) and heart failure (HF). Interestingly, novel investigations show that AT1 antagonists (sartans) are able to broaden their therapeutic scope and potentially combat other diseases such as neurodegenerative diseases, cancer, and osteoarthritis, and even help people with methamphetamine and opioid addiction.<\/jats:p>","DOI":"10.3390\/ijms26188819","type":"journal-article","created":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T14:14:55Z","timestamp":1757513695000},"page":"8819","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Unlocking Novel Therapeutic Potential of Angiotensin II Receptor Blockers"],"prefix":"10.3390","volume":"26","author":[{"given":"Filippos Panteleimon","family":"Chatzipieris","sequence":"first","affiliation":[{"name":"Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiriaki","family":"Mavromoustakou","sequence":"additional","affiliation":[{"name":"First Cardiology Department, Medical School, National and Kapodistrian University of Athens, Hippokration General Hospital, 11527 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5554-2964","authenticated-orcid":false,"given":"John M.","family":"Matsoukas","sequence":"additional","affiliation":[{"name":"Institute for Health and Sport, Victoria University, Melbourne, VIC 3030, Australia"},{"name":"Department of Physiology and Pharmacology, Cumming School of Medicine, University of Calgary, Calgary, AB T2N 4N1, Canada"},{"name":"NewDrug, P.C., Patras Science Park, 26504 Patras, Greece"},{"name":"Department of Chemistry, University of Patras, 26504 Patras, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5309-992X","authenticated-orcid":false,"given":"Thomas","family":"Mavromoustakos","sequence":"additional","affiliation":[{"name":"Laboratory of Organic Chemistry, Department of Chemistry, National and Kapodistrian University of Athens, 15771 Athens, Greece"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,9,10]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"e1597","DOI":"10.1002\/wcms.1597","article-title":"Deep Learning for Drug Repurposing: Methods, Databases, and Applications","volume":"12","author":"Pan","year":"2022","journal-title":"WIREs Comput. Mol. Sci."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1016\/j.drudis.2019.06.014","article-title":"Drug Repurposing: A Promising Tool to Accelerate the Drug Discovery Process","volume":"24","author":"Parvathaneni","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1007\/s43440-020-00155-6","article-title":"Drug Repurposing Approach to Fight COVID-19","volume":"72","author":"Singh","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1134\/S1068162023020139","article-title":"Drug Repurposing: An Effective Tool in Modern Drug Discovery","volume":"49","author":"Kulkarni","year":"2023","journal-title":"Russ. J. Bioorg. Chem."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.ygeno.2019.06.021","article-title":"Drug Databases and Their Contributions to Drug Repurposing","volume":"112","author":"Omidi","year":"2020","journal-title":"Genomics"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1093\/bib\/bbaa288","article-title":"A Review on Drug Repurposing Applicable to COVID-19","volume":"22","author":"Dotolo","year":"2021","journal-title":"Brief. Bioinform."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1043","DOI":"10.1016\/j.csbj.2020.04.004","article-title":"Drug Repositioning or Target Repositioning: A Structural Perspective of Drug-Target-Indication Relationship for Available Repurposed Drugs","volume":"18","author":"Parisi","year":"2020","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"915","DOI":"10.1021\/acsptsci.3c00361","article-title":"Drug Repurposing: A Leading Strategy for New Threats and Targets","volume":"7","author":"Mishra","year":"2024","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1007\/s10557-006-9799-9","article-title":"Efficacy of Angiotensin Receptor Blockers in Cardiovascular Disease","volume":"20","author":"Maggioni","year":"2006","journal-title":"Cardiovasc. Drugs Ther."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1080\/080370502321095285","article-title":"The Angiotensin-Receptor Blockers: From Antihypertensives to Cardiovascular All-Round Medications in 10 Years?","volume":"11","author":"Maggioni","year":"2002","journal-title":"Blood Press."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"e12306","DOI":"10.1111\/1755-5922.12306","article-title":"Alamandine Reverses Hyperhomocysteinemia-induced Vascular Dysfunction via PKA-dependent Mechanisms","volume":"35","author":"Qaradakhi","year":"2017","journal-title":"Cardiovasc. Ther."},{"key":"ref_12","first-page":"183","article-title":"The Angiotensin II Receptor Blockers: Opportunities across the Spectrum of Cardiovascular Disease","volume":"3","author":"Weber","year":"2002","journal-title":"Rev. Cardiovasc. Med."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-Target-Directed Ligands To Combat Neurodegenerative Diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Brindisi, M., Kessler, S.M., Kumar, V., and Zwergel, C. (2022). Editorial: Multi-Target Directed Ligands for the Treatment of Cancer. Front. Oncol., 12.","DOI":"10.3389\/fonc.2022.980141"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.2147\/DDDT.S257494","article-title":"Potential Impact of the Multi-Target Drug Approach in the Treatment of Some Complex Diseases","volume":"14","author":"Makhoba","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.2174\/0929867328666210512005508","article-title":"Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer\u2019s Disease","volume":"29","author":"Kumar","year":"2022","journal-title":"Curr. Med. Chem."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1038\/ajg.2013.407","article-title":"How Drugs Are Developed and Approved by the FDA: Current Process and Future Directions","volume":"109","author":"Ciociola","year":"2014","journal-title":"Am. J. Gastroenterol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"c125","DOI":"10.1159\/000232592","article-title":"Drug Development: From Concept to Marketing!","volume":"113","author":"Tamimi","year":"2009","journal-title":"Nephron Clin. Pract."},{"key":"ref_19","first-page":"48","article-title":"An Overview of the Drug Development Process","volume":"31","author":"Tonkens","year":"2005","journal-title":"Physician Exec."},{"key":"ref_20","first-page":"578","article-title":"Preclinical Drug Development","volume":"67","author":"Brodniewicz","year":"2010","journal-title":"Acta Pol. Pharm."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Singh, G. (2018). Preclinical Drug Development. Pharmaceutical Medicine and Translational Clinical Research, Elsevier.","DOI":"10.1016\/B978-0-12-802103-3.00004-3"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1038\/nrd.2018.168","article-title":"Drug Repurposing: Progress, Challenges and Recommendations","volume":"18","author":"Pushpakom","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","first-page":"S15","article-title":"Regulatory Framework for Drug Development in Rare Diseases","volume":"62","year":"2022","journal-title":"J. Clin. Pharmacol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.therap.2020.02.006","article-title":"Drug Repurposing in Rare Diseases: Myths and Reality","volume":"75","author":"Fetro","year":"2020","journal-title":"Therapies"},{"key":"ref_25","doi-asserted-by":"crossref","unstructured":"R\u00e9da, C., Vie, J.-J., and Wolkenhauer, O. (2025). Comprehensive Evaluation of Pure and Hybrid Collaborative Filtering in Drug Repurposing. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-85927-x"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/nrd2030","article-title":"Sildenafil: From Angina to Erectile Dysfunction to Pulmonary Hypertension and Beyond","volume":"5","author":"Ghofrani","year":"2006","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1016\/0006-291X(90)92168-Y","article-title":"Nitric Oxide and Cyclic GMP For-mation upon Electrical Field Stimulation Cause Relaxation of Corpus Cavernosum Smooth Muscle","volume":"170","author":"Ignarro","year":"1990","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_28","first-page":"1","article-title":"Duloxetine: An Update","volume":"13","year":"2024","journal-title":"Res. Soc. Dev."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"193","DOI":"10.2147\/nedt.2007.3.2.193","article-title":"Duloxetine in the Treatment of Major Depressive Disorder","volume":"3","author":"Goldstein","year":"2007","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_30","first-page":"CD007115","article-title":"Duloxetine for Treating Painful Neuropathy, Chronic Pain or Fibromyalgia","volume":"1","author":"Lunn","year":"2014","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_31","first-page":"23","article-title":"Duloxetine for the Treatment of Generalized Anxiety Disorder: A Review","volume":"5","author":"Khan","year":"2009","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"e17541","DOI":"10.1097\/MD.0000000000017541","article-title":"The Short-Term Effect and Safety of Duloxetine in Osteoarthritis: A Systematic Review and Meta-Analysis","volume":"98","author":"Gao","year":"2019","journal-title":"Medicine"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4274\/jus.galenos.2022.2022.0027","article-title":"Duloxetine in the Treatment of Women with Urinary Incontinence: A Systematic Review and Meta-Analysis of Efficacy Data from Randomized Controlled Clinical Trials","volume":"10","author":"Demirkesen","year":"2023","journal-title":"J. Urol. Surg."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1038\/nrd1821","article-title":"The Discovery of Fluoxetine Hydrochloride (Prozac)","volume":"4","author":"Wong","year":"2005","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1016\/S0149-2918(00)88315-0","article-title":"The Role of Fluoxetine in the Treatment of Premenstrual Dysphoric Disorder","volume":"21","author":"Romano","year":"1999","journal-title":"Clin. Ther."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1097\/JCP.0000000000000963","article-title":"The Role of Atomoxetine for Parkinson Disease\u2013Related Executive Dysfunction: A Systematic Review","volume":"38","author":"Warner","year":"2018","journal-title":"J. Clin. Psychopharmacol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/j.euroneuro.2009.07.008","article-title":"Atomoxetine Hydrochloride in the Treatment of Children and Adolescents with Attention-Deficit\/Hyperactivity Disorder and Comorbid Oppositional Defiant Disorder: A Placebo-Controlled Italian Study","volume":"19","author":"Maschietto","year":"2009","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1136\/jnnp.39.2.184","article-title":"Bromocriptine Treatment in Parkinson\u2019s Disease","volume":"39","author":"Parkes","year":"1976","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"789","DOI":"10.2337\/dc11-0064","article-title":"Bromocriptine: A Sympatholytic, D2-Dopamine Agonist for the Treatment of Type 2 Diabetes","volume":"34","author":"DeFronzo","year":"2011","journal-title":"Diabetes Care"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"71","DOI":"10.14791\/btrt.2013.1.2.71","article-title":"Bromocriptine Therapy for the Treatment of Invasive Prolactinoma: The Single Institute Experience","volume":"1","author":"Cho","year":"2013","journal-title":"Brain Tumor Res. Treat."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"329","DOI":"10.4088\/JCP.v61n0502","article-title":"Clozapine for Treatment-Refractory Schizophrenia, Schizoaffective Disorder, and Psychotic Bipolar Disorder: A 24-Month Naturalistic Study","volume":"61","author":"Ciapparelli","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1038\/s41416-025-02992-9","article-title":"Repurposing Chlorpromazine for the Treatment of Triple-Negative Breast Cancer Growth and Metastasis Based on Modulation of Mitochondria-Mediated Apoptosis and Autophagy\/Mitophagy","volume":"132","author":"Pu","year":"2025","journal-title":"Br. J. Cancer"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1111\/j.1755-5949.2011.00260.x","article-title":"Lithium: Still a Major Option in the Management of Bipolar Disorder","volume":"18","author":"Licht","year":"2012","journal-title":"CNS Neurosci. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","unstructured":"Ge, W., and Jakobsson, E. (2019). Systems Biology Understanding of the Effects of Lithium on Cancer. Front. Oncol., 9.","DOI":"10.3389\/fonc.2019.00296"},{"key":"ref_45","doi-asserted-by":"crossref","unstructured":"Chatupheeraphat, C., Kaewsai, N., Anuwongcharoen, N., Phanus-umporn, C., Pornsuwan, S., and Eiamphungporn, W. (2025). Penfluridol Synergizes with Colistin to Reverse Colistin Resistance in Gram-Negative Bacilli. Sci. Rep., 15.","DOI":"10.1038\/s41598-025-01303-9"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"174","DOI":"10.3892\/or.2024.8833","article-title":"Repurposing the Antipsychotic Drug Penfluridol for Cancer Treatment (Review)","volume":"52","year":"2024","journal-title":"Oncol. Rep."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/0014-2999(94)90218-6","article-title":"Tolerance to Peripheral, but Not Central, Effects of Ropinirole, a Selective Dopamine D2-like Receptor Agonist","volume":"265","author":"Parker","year":"1994","journal-title":"Eur. J. Pharmacol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"e27653","DOI":"10.1097\/MD.0000000000027653","article-title":"The Effect and Safety of Ropinirole in the Treatment of Parkinson Disease: A Systematic Review and Meta-Analysis","volume":"100","author":"Zhu","year":"2021","journal-title":"Medicine"},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Werz, O., Stettler, H., Theurer, C., and Seibel, J. (2024). The 125th Anniversary of Aspirin\u2014The Story Continues. Pharmaceuticals, 17.","DOI":"10.3390\/ph17040437"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"2285","DOI":"10.1182\/blood-2006-01-010645","article-title":"Antithrombotic Properties of Aspirin and Resistance to Aspirin: Beyond Strictly Antiplatelet Actions","volume":"109","author":"Undas","year":"2007","journal-title":"Blood"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"957","DOI":"10.2165\/00003495-200059040-00017","article-title":"Celecoxib: A Review of Its Use in Osteoarthritis, Rheumatoid Arthritis and Acute Pain","volume":"59","author":"Clemett","year":"2000","journal-title":"Drugs"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/ajg.2009.758","article-title":"The Safety and Efficacy of Celecoxib in Children With Familial Adenomatous Polyposis","volume":"105","author":"Lynch","year":"2010","journal-title":"Am. J. Gastroenterol."},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Edwards, J.E., and Moore, R.A. (2002). Finasteride in the Treatment of Clinical Benign Prostatic Hyperplasia: A Systematic Review of Randomised Trials. BMC Urol., 2.","DOI":"10.1186\/1471-2490-2-14"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1080\/09546634.2021.1959506","article-title":"Finasteride for Hair Loss: A Review","volume":"33","author":"Gupta","year":"2022","journal-title":"J. Dermatol. Treat."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"227","DOI":"10.2165\/00002512-200016030-00006","article-title":"Losartan: A Review of Its Use, with Special Focus on Elderly Patients","volume":"16","author":"Simpson","year":"2000","journal-title":"Drugs Aging"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1211","DOI":"10.15252\/emmm.201505061","article-title":"Losartan Ameliorates Dystrophic Epidermolysis Bullosa and Uncovers New Disease Mechanisms","volume":"7","author":"Thriene","year":"2015","journal-title":"EMBO Mol. Med."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"103818","DOI":"10.1016\/j.isci.2022.103818","article-title":"Attenuation of SARS-CoV-2 Infection by Losartan in Human Kidney Organoids","volume":"25","author":"Rahmani","year":"2022","journal-title":"iScience"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/jama.1975.03260030039018","article-title":"Severe Hypertension: Treatment with Minoxidil","volume":"233","author":"Mehta","year":"1975","journal-title":"JAMA"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.jaad.2020.06.1009","article-title":"Oral Minoxidil Treatment for Hair Loss: A Review of Efficacy and Safety","volume":"84","author":"Randolph","year":"2021","journal-title":"J. Am. Acad. Dermatol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1086\/597290","article-title":"Raltegravir: The First HIV Type 1 Integrase Inhibitor","volume":"48","author":"Hicks","year":"2009","journal-title":"Clin Infect. Dis."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Alburquerque-Gonz\u00e1lez, B., Bernab\u00e9-Garc\u00eda, \u00c1., Bernab\u00e9-Garc\u00eda, M., Ruiz-Sanz, J., L\u00f3pez-Calder\u00f3n, F.F., Gonnelli, L., Banci, L., Pe\u00f1a-Garc\u00eda, J., Luque, I., and Nicol\u00e1s, F.J. (2021). The FDA-Approved Antiviral Raltegravir Inhibits Fascin1-Dependent Invasion of Colorectal Tumor Cells In Vitro and In Vivo. Cancers, 13.","DOI":"10.3390\/cancers13040861"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.antiviral.2009.10.002","article-title":"The Development of Antiretroviral Therapy and Its Impact on the HIV-1\/AIDS Pandemic","volume":"85","author":"Broder","year":"2010","journal-title":"Antivir. Res."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"408","DOI":"10.2165\/00003495-198937040-00003","article-title":"Zidovudine: A Review of Its Pharmacodynamic and Pharmacokinetic Properties, and Therapeutic Efficacy","volume":"37","author":"Langtry","year":"1989","journal-title":"Drugs"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"108272","DOI":"10.1016\/j.intimp.2021.108272","article-title":"Auranofin: Past to Present, and Repurposing","volume":"101","author":"Yamashita","year":"2021","journal-title":"Int. Immunopharmacol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1158\/1535-7163.MCT-12-0968","article-title":"Drug Repurposing for Gastrointestinal Stromal Tumor","volume":"12","author":"Pessetto","year":"2013","journal-title":"Mol. Cancer Ther."},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"e29602","DOI":"10.1002\/pbc.29602","article-title":"FDA Approval Summary: Crizotinib for Pediatric and Young Adult Patients with Relapsed or Refractory Systemic Anaplastic Large Cell Lymphoma","volume":"69","author":"Merino","year":"2022","journal-title":"Pediatr. Blood Cancer"},{"key":"ref_67","first-page":"91","article-title":"Clinical Use of Crizotinib for the Treatment of Non-Small Cell Lung Cancer","volume":"7","author":"Roberts","year":"2013","journal-title":"Biologics"},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"e2014007","DOI":"10.4084\/mjhid.2014.007","article-title":"Imatinib in Chronic Myeloid Leukemia: An Overview","volume":"6","author":"Sacha","year":"2014","journal-title":"Mediterr. J. Hematol. Infect. Dis."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1111\/j.1582-4934.2009.00983.x","article-title":"Imatinib Treatment for Gastrointestinal Stromal Tumour (GIST)","volume":"14","author":"Lopes","year":"2010","journal-title":"J. Cell. Mol. Med."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"12234","DOI":"10.3748\/wjg.v21.i43.12234","article-title":"Irinotecan, a Key Chemotherapeutic Drug for Metastatic Colorectal Cancer","volume":"21","author":"Fujita","year":"2015","journal-title":"World J. Gastroenterol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1007\/s40265-024-02133-1","article-title":"Liposomal Irinotecan: A Review as First-Line Therapy in Metastatic Pancreatic Adenocarcinoma","volume":"85","author":"Brown","year":"2025","journal-title":"Drugs"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/dom.15663","article-title":"Metformin: Therapeutic Profile in the Treatment of Type 2 Diabetes","volume":"26","author":"Bailey","year":"2024","journal-title":"Diabetes Obes. Metab."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1093\/jnci\/djae070","article-title":"Metformin Boosts Antitumor Immunity and Improves Prognosis in Upfront Resected Pancreatic Cancer: An Observational Study","volume":"116","author":"Vadgama","year":"2024","journal-title":"JNCI J. Natl. Cancer Inst."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Lee, T.Y., Martinez-Outschoorn, U.E., Schilder, R.J., Kim, C.H., Richard, S.D., Rosenblum, N.G., and Johnson, J.M. (2018). Metformin as a Therapeutic Target in Endometrial Cancers. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00341"},{"key":"ref_75","doi-asserted-by":"crossref","unstructured":"Higurashi, T., and Nakajima, A. (2018). Metformin and Colorectal Cancer. Front. Endocrinol., 9.","DOI":"10.3389\/fendo.2018.00622"},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"778","DOI":"10.4143\/crt.2015.485","article-title":"Effects and Mechanisms of Metformin on the Proliferation of Esophageal Cancer Cells In Vitro and In Vivo","volume":"49","author":"Tang","year":"2017","journal-title":"Cancer Res. Treat."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1189\/jlb.0911447","article-title":"The HIV-1 Protease Inhibitor Nelfinavir Activates PP2 and Inhibits MAPK Signaling in Macrophages: A Pathway to Reduce Inflammation","volume":"92","author":"Wallet","year":"2012","journal-title":"J. Leukoc. Biol."},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Subeha, M.R., and Telleria, C.M. (2020). The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir. Cancers, 12.","DOI":"10.3390\/cancers12113437"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1517\/14656566.2013.782002","article-title":"The Use of Raloxifene in Osteoporosis Treatment","volume":"14","author":"Isaia","year":"2013","journal-title":"Expert Opin. Pharmacother."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.2165\/00003495-200868140-00008","article-title":"Raloxifene: A Review of Its Use in the Prevention of Invasive Breast Cancer","volume":"68","author":"Moen","year":"2008","journal-title":"Drugs"},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Pierpont, T.M., Limper, C.B., and Richards, K.L. (2018). Past, Present, and Future of Rituximab\u2014The World\u2019s First Oncology Monoclonal Antibody Therapy. Front. Oncol., 8.","DOI":"10.3389\/fonc.2018.00163"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1007\/s40744-015-0016-9","article-title":"Rituximab for Rheumatoid Arthritis","volume":"2","author":"Cohen","year":"2015","journal-title":"Rheumatol. Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1177\/1756287217713902","article-title":"Sunitinib in the Treatment of Renal Cell Carcinoma: An Update on Recent Evidence","volume":"9","author":"Rizzo","year":"2017","journal-title":"Ther. Adv. Urol."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"7573","DOI":"10.2147\/OTT.S101385","article-title":"Sunitinib in the Treatment of Gastrointestinal Stromal Tumor: Patient Selection and Perspectives","volume":"9","year":"2016","journal-title":"Onco Targets Ther."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1056\/NEJMoa1003825","article-title":"Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors","volume":"364","author":"Raymond","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1200\/JGO.19.00299","article-title":"Effectiveness of Trastuzumab for Human Epidermal Growth Factor Receptor 2\u2013Positive Breast Cancer in a Real-Life Setting: One Decade of Experience Under National Treatment Coverage Regulations","volume":"6","author":"Camejo","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"179","DOI":"10.4137\/CMO.S6460","article-title":"Trastuzumab for HER2-Positive Metastatic Breast Cancer: Clinical and Economic Considerations","volume":"6","author":"Jeyakumar","year":"2012","journal-title":"Clin. Med. Insights Oncol."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1177\/1758834012469429","article-title":"Gastric Cancer and Trastuzumab: First Biologic Therapy in Gastric Cancer","volume":"5","author":"Gunturu","year":"2013","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (EBCTCG) (2021). Trastuzumab for Early-Stage, HER2-Positive Breast Cancer: A Meta-Analysis of 13\u2008864 Women in Seven Randomised Trials. Lancet Oncol., 22, 1139\u20131150."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1634\/theoncologist.2009-0178","article-title":"FDA Approval Summary: Temsirolimus as Treatment for Advanced Renal Cell Carcinoma","volume":"15","author":"Kwitkowski","year":"2010","journal-title":"Oncologist"},{"key":"ref_91","doi-asserted-by":"crossref","unstructured":"Chang, H.-W., Wu, M.-J., Lin, Z.-M., Wang, C.-Y., Cheng, S.-Y., Lin, Y.-K., Chow, Y.-H., Ch\u2019ang, H.-J., and Chang, V.H.S. (2018). Therapeutic Effect of Repurposed Temsirolimus in Lung Adenocarcinoma Model. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00778"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Mesa-Arango, A.C., Scorzoni, L., and Zaragoza, O. (2012). It Only Takes One to Do Many Jobs: Amphotericin B as Antifungal and Immunomodulatory Drug. Front. Microbiol., 3.","DOI":"10.3389\/fmicb.2012.00286"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1517\/14728214.2012.748036","article-title":"Liposomal Amphotericin B as a Treatment for Human Leishmaniasis","volume":"17","author":"Balasegaram","year":"2012","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"e94","DOI":"10.1097\/IOP.0000000000000806","article-title":"Retrobulbar Injection of Amphotericin B for Orbital Mucormycosis","volume":"33","author":"Hirabayashi","year":"2017","journal-title":"Ophthalmic Plast. Reconstr. Surg."},{"key":"ref_95","first-page":"100473-1","article-title":"Efficacy of Dapoxetine in the Treatment of Patients With Lifelong Premature Ejaculation as an Alternative to Sertraline Therapy","volume":"10","author":"Liu","year":"2022","journal-title":"Sex. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Zhang, B., Yu, J., Zhu, G., Huang, Y., Zhang, K., Xiao, X., He, W., Yuan, J., and Gao, X. (2023). Dapoxetine, a Selective Serotonin Reuptake Inhibitor, Suppresses Zika Virus Infection In Vitro. Molecules, 28.","DOI":"10.3390\/molecules28248142"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"990","DOI":"10.4254\/wjh.v9.i23.990","article-title":"Use of Everolimus in Liver Transplantation","volume":"9","author":"Yee","year":"2017","journal-title":"World J. Hepatol."},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Medici, B., Caffari, E., Maculan, Y., Benatti, S., Piacentini, F., Dominici, M., and Gelsomino, F. (2025). Everolimus in the Treatment of Neuroendocrine Tumors: Lights and Shadows. Biomedicines, 13.","DOI":"10.3390\/biomedicines13020455"},{"key":"ref_99","first-page":"91","article-title":"Everolimus: The First Approved Product for Patients with Advanced Renal Cell Cancer after Sunitinib and\/or Sorafenib","volume":"4","author":"Coppin","year":"2010","journal-title":"Biologics"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1056\/NEJMoa1001671","article-title":"Everolimus for Subependymal Giant-Cell Astrocytomas in Tuberous Sclerosis","volume":"363","author":"Krueger","year":"2010","journal-title":"N. Engl. J. Med."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"107512","DOI":"10.1016\/j.pharmthera.2020.107512","article-title":"Favipiravir, an Anti-Influenza Drug against Life-Threatening RNA Virus Infections","volume":"209","author":"Shiraki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1007\/s43440-020-00175-2","article-title":"Favipiravir Use for SARS-CoV-2 Infection","volume":"72","author":"Boretti","year":"2020","journal-title":"Pharmacol. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1038\/ja.2017.11","article-title":"Ivermectin: Enigmatic Multifaceted \u2018Wonder\u2019 Drug Continues to Surprise and Exceed Expectations","volume":"70","author":"Crump","year":"2017","journal-title":"J. Antibiot."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1016\/j.jconrel.2020.10.009","article-title":"Ivermectin: An Award-Winning Drug with Expected Antiviral Activity against COVID-19","volume":"329","author":"Formiga","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/00003495-198223010-00001","article-title":"Ketoconazole: A Review of Its Therapeutic Efficacy in Superficial and Systemic Fungal Infections","volume":"23","author":"Heel","year":"1982","journal-title":"Drugs"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1210\/jcem-63-6-1365","article-title":"Use of Ketoconazole in the Treatment of Cushing\u2019s Syndrome","volume":"63","author":"Loli","year":"1986","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/bs.podrm.2022.11.003","article-title":"Remdesivir","volume":"Volume 48","author":"Bakheit","year":"2023","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_108","doi-asserted-by":"crossref","unstructured":"Jeon, H.J., Lee, H.-E., and Yang, J. (2018). Safety and Efficacy of Rapamune\u00ae (Sirolimus) in Kidney Transplant Recipients: Results of a Prospective Post-Marketing Surveillance Study in Korea. BMC Nephrol., 19.","DOI":"10.1186\/s12882-018-1002-6"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1186\/s12936-017-2092-5","article-title":"A Single Rapamycin Dose Protects against Late-Stage Experimental Cerebral Malaria via Modulation of Host Immunity, Endothelial Activation and Parasite Sequestration","volume":"16","author":"Mejia","year":"2017","journal-title":"Malar. J."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1592\/phco.23.4.481.32115","article-title":"Thalidomide for Erythema Nodosum Leprosum and Other Applications","volume":"23","author":"Okafor","year":"2003","journal-title":"Pharmacotherapy"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1186\/2162-3619-1-27","article-title":"Thalidomide and Its Analogues in the Treatment of Multiple Myeloma","volume":"1","author":"Latif","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_112","first-page":"411","article-title":"The Safety and Efficacy of Alefacept in the Treatment of Chronic Plaque Psoriasis","volume":"3","author":"Jenneck","year":"2007","journal-title":"Ther. Clin. Risk Manag."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"1000104","DOI":"10.4172\/2471-9552.1000104","article-title":"Can We Repurpose FDA-Approved Alefacept to Diminish the HIV Reservoir?","volume":"1","author":"Zaidi","year":"2016","journal-title":"Immunother. Open Acc."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/jgs.18665","article-title":"Baclofen and the Risk of Fall and Fracture in Older Adults: A Real-world Cohort Study","volume":"72","author":"Hwang","year":"2024","journal-title":"J. Am. Geriatr. Soc."},{"key":"ref_115","doi-asserted-by":"crossref","unstructured":"de Beaurepaire, R., Sinclair, J.M.A., Heydtmann, M., Addolorato, G., Aubin, H.-J., Beraha, E.M., Caputo, F., Chick, J.D., de La Selle, P., and Franchitto, N. (2018). The Use of Baclofen as a Treatment for Alcohol Use Disorder: A Clinical Practice Perspective. Front. Psychiatry, 9.","DOI":"10.3389\/fpsyt.2018.00708"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"397","DOI":"10.2165\/11311020-000000000-00000","article-title":"Topical Clobetasol Propionate in the Treatment of Psoriasis: A Review of Newer Formulations","volume":"10","author":"Feldman","year":"2009","journal-title":"Am. J. Clin. Dermatol."},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"6395","DOI":"10.1097\/MS9.0000000000002619","article-title":"Clobetasol Propionate for Post-Cataract Surgery Pain and Inflammation","volume":"86","author":"Azhar","year":"2024","journal-title":"Ann. Med. Surg."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Mills, E.A., Ogrodnik, M.A., Plave, A., and Mao-Draayer, Y. (2018). Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis. Front. Neurol., 9.","DOI":"10.3389\/fneur.2018.00005"},{"key":"ref_119","first-page":"9613","article-title":"Real-World Use of Dimethyl Fumarate in Patients with Plaque Psoriasis: A Delphi-Based Expert Consensus","volume":"15","author":"Burlando","year":"2023","journal-title":"Dermatol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","unstructured":"McGuire, V.A., Ruiz-Zorrilla Diez, T., Emmerich, C.H., Strickson, S., Ritorto, M.S., Sutavani, R.V., Wei\u03b2, A., Houslay, K.F., Knebel, A., and Meakin, P.J. (2016). Dimethyl Fumarate Blocks Pro-Inflammatory Cytokine Production via Inhibition of TLR Induced M1 and K63 Ubiquitin Chain Formation. Sci. Rep., 6.","DOI":"10.1038\/srep31159"},{"key":"ref_121","first-page":"195","article-title":"Erythropoietin Stimulating Agents in the Management of Anemia of Chronic Kidney Disease","volume":"2","author":"Hayat","year":"2008","journal-title":"Patient Prefer. Adherence"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s00134-023-07141-5","article-title":"The Effect of Recombinant Erythropoietin on Long-Term Outcome after Moderate-to-Severe Traumatic Brain Injury","volume":"49","author":"Skrifvars","year":"2023","journal-title":"Intensive Care Med."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jpag.2022.02.002","article-title":"The Care of Adolescents and Young Adults with Turner Syndrome: A Pediatric and Adolescent Gynecology Perspective","volume":"35","author":"Shankar","year":"2022","journal-title":"J. Pediatr. Adolesc. Gynecol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S1526-9523(02)00234-9","article-title":"CONTRACEPTIVE APPLICATIONS OF ESTROGEN","volume":"47","author":"Likis","year":"2002","journal-title":"J. Midwifery Women\u2019s Health"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1093\/humrep\/dem379","article-title":"Cyproterone Acetate\/Ethinyl Estradiol for Acne and Hirsutism: Time to Revise Prescribing Policy","volume":"23","author":"Franks","year":"2007","journal-title":"Hum. Reprod."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1056\/NEJMct1101691","article-title":"Fingolimod for Multiple Sclerosis","volume":"366","author":"Pelletier","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00702-023-02618-5","article-title":"Repurposing Drugs against Alzheimer\u2019s Disease: Can the Anti-Multiple Sclerosis Drug Fingolimod (FTY720) Effectively Tackle Inflammation Processes in AD?","volume":"130","author":"Kartalou","year":"2023","journal-title":"J. Neural Transm."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/jcmm.12635","article-title":"The Antineoplastic Properties of FTY720: Evidence for the Repurposing of Fingolimod","volume":"19","author":"Patmanathan","year":"2015","journal-title":"J. Cell. Mol. Med."},{"key":"ref_129","doi-asserted-by":"crossref","unstructured":"Gesualdo, C., Balta, C., Platania, C.B.M., Trotta, M.C., Herman, H., Gharbia, S., Rosu, M., Petrillo, F., Giunta, S., and Della Corte, A. (2021). Fingolimod and Diabetic Retinopathy: A Drug Repurposing Study. Front. Pharmacol., 12.","DOI":"10.3389\/fphar.2021.718902"},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1586\/14779072.2015.1054810","article-title":"Liraglutide for Type 2 Diabetes and Obesity: A 2015 Update","volume":"13","author":"Iepsen","year":"2015","journal-title":"Expert Rev. Cardiovasc. Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e057848","DOI":"10.1002\/alz.057848","article-title":"Evaluation of Liraglutide in the Treatment of Alzheimer\u2019s Disease","volume":"17","author":"Edison","year":"2021","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1177\/1753465812437563","article-title":"N.-Acetylcysteine Mucolysis in the Management of Chronic Obstructive Pulmonary Disease","volume":"6","author":"Sadowska","year":"2012","journal-title":"Ther. Adv. Respir. Dis."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"e14653","DOI":"10.1111\/cns.14653","article-title":"The Promise of N-Acetylcysteine in the Treatment of Obsessive-Compulsive Disorder","volume":"30","author":"Carollo","year":"2024","journal-title":"CNS Neurosci. Ther."},{"key":"ref_134","first-page":"CD007076","article-title":"Pregabalin for Neuropathic Pain in Adults","volume":"1","author":"Derry","year":"2019","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_135","first-page":"883","article-title":"Pregabalin for the Treatment of Generalized Anxiety Disorder: An Update","volume":"9","author":"Baldwin","year":"2013","journal-title":"Nephrol. Dial. Transplant."},{"key":"ref_136","first-page":"CD004816","article-title":"Statins for the Primary Prevention of Cardiovascular Disease","volume":"2013","author":"Taylor","year":"2013","journal-title":"Cochrane Database Syst. Rev."},{"key":"ref_137","first-page":"e2078","article-title":"Statins as Anti-Tumor Agents: A Paradigm for Repurposed Drugs","volume":"7","author":"Tripathi","year":"2024","journal-title":"Cancer Rep."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"100012","DOI":"10.1016\/j.crphar.2020.100012","article-title":"Perspective Insights of Repurposing the Pleiotropic Efficacy of Statins in Neurodegenerative Disorders: An Expository Appraisal","volume":"2","author":"Bhat","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discov."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2743","DOI":"10.1096\/fj.201801104R","article-title":"Repurposing Simvastatin as a Therapy for Preterm Labor: Evidence from Preclinical Models","volume":"33","author":"Boyle","year":"2019","journal-title":"FASEB J."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1080\/08927014.2024.2413652","article-title":"Repurposing Simvastatin for Treatment of Klebsiella Pneumoniae Infections: In Vitro and in Vivo Study","volume":"40","author":"Moglad","year":"2024","journal-title":"Biofouling"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"2231","DOI":"10.2165\/00003495-200767150-00008","article-title":"Topiramate: A Review of Its Use in the Treatment of Epilepsy","volume":"67","author":"Yang","year":"2007","journal-title":"Drugs"},{"key":"ref_142","doi-asserted-by":"crossref","unstructured":"Wajid, I., Vega, A., Thornhill, K., Jenkins, J., Merriman, C., Chandler, D., Shekoohi, S., Cornett, E.M., and Kaye, A.D. (2023). Topiramate (Topamax): Evolving Role in Weight Reduction Management: A Narrative Review. Life, 13.","DOI":"10.3390\/life13091845"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"59","DOI":"10.12793\/tcp.2019.27.2.59","article-title":"A Review of Computational Drug Repurposing","volume":"27","author":"Park","year":"2019","journal-title":"Transl. Clin. Pharmacol."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"8","DOI":"10.33393\/dti.2024.3019","article-title":"The Dark Side of Drug Repurposing. From Clinical Trial Challenges to Antimicrobial Resistance: Analysis Based on Three Major Fields","volume":"18","author":"Natsheh","year":"2024","journal-title":"Drug Target Insights"},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"102504","DOI":"10.1016\/j.jflm.2023.102504","article-title":"Rare Fatal Effect of Combined Use of Sildenafil and Alcohol Leading to Cerebrovascular Accident","volume":"95","author":"Pandit","year":"2023","journal-title":"J. Forensic Leg. Med."},{"key":"ref_146","unstructured":"Singh, B., Cusick, A.S., Goyal, A., and Patel, P. (2025). ACE Inhibitors. StatPearls, StatPearls Publishing."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/BF01116558","article-title":"Angiotensin as a Model for Hormone\u2014Receptor Interactions","volume":"5","author":"Moore","year":"1985","journal-title":"Biosci. Rep."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"5303","DOI":"10.1016\/S0021-9258(17)37688-3","article-title":"Role of the NH2-Terminal Domain of Angiotensin II (ANG II) and [Sar1]Angiotensin II on Conformation and Activity. NMR Evidence for Aromatic Ring Clustering and Peptide Backbone Folding Compared with [Des-1,2,3]Angiotensin II","volume":"269","author":"Matsoukas","year":"1994","journal-title":"J. Biol. Chem."},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"780","DOI":"10.1021\/jm00383a015","article-title":"Synthesis and Biological Activities of Analogs of Angiotensins II and III Containing O-Methyltyrosine and D-Tryptophan","volume":"28","author":"Matsoukas","year":"1985","journal-title":"J. Med. Chem."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1021\/jm00402a028","article-title":"Importance of the N-Terminal Domain of the Type II Angiotensin Antagonist Sarmesin for Receptor Blockade","volume":"31","author":"Matsoukas","year":"1988","journal-title":"J. Med. Chem."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"101622","DOI":"10.1016\/j.cpcardiol.2023.101622","article-title":"Global Cardiovascular Diseases Death Rate Prediction","volume":"48","author":"Gaidai","year":"2023","journal-title":"Curr. Probl. Cardiol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/eurjpc\/zwae281","article-title":"Global Burden of Cardiovascular Diseases: Projections from 2025 to 2050","volume":"32","author":"Chong","year":"2024","journal-title":"Eur. J. Prev. Cardiol."},{"key":"ref_153","first-page":"e41","article-title":"2025 Heart Disease and Stroke Statistics: A Report of US and Global Data From the American Heart Association","volume":"151","author":"Martin","year":"2025","journal-title":"Circulation"},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"e2160","DOI":"10.1097\/MD.0000000000002160","article-title":"High Blood Pressure and All-Cause and Cardiovascular Disease Mortalities in Community-Dwelling Older Adults","volume":"94","author":"Wu","year":"2015","journal-title":"Medicine"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1016\/S0140-6736(15)01225-8","article-title":"Blood Pressure Lowering for Prevention of Cardiovascular Disease and Death: A Systematic Review and Meta-Analysis","volume":"387","author":"Ettehad","year":"2016","journal-title":"Lancet"},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1093\/eurheartj\/ehae178","article-title":"2024 ESC Guidelines for the Management of Elevated Blood Pressure and Hypertension","volume":"45","author":"McEvoy","year":"2024","journal-title":"Eur. Heart J."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","article-title":"Temporal Trends and Patterns in Heart Failure Incidence: A Population-Based Study of 4 Million Individuals","volume":"391","author":"Conrad","year":"2018","journal-title":"Lancet"},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"3599","DOI":"10.1093\/eurheartj\/ehab368","article-title":"2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"42","author":"McDonagh","year":"2021","journal-title":"Eur. Heart J."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1007\/s10741-021-10137-2","article-title":"Current and Emerging Drug Targets in Heart Failure Treatment","volume":"27","author":"Ghionzoli","year":"2022","journal-title":"Heart Fail. Rev."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"3627","DOI":"10.1093\/eurheartj\/ehad195","article-title":"2023 Focused Update of the 2021 ESC Guidelines for the Diagnosis and Treatment of Acute and Chronic Heart Failure","volume":"44","author":"McDonagh","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_161","doi-asserted-by":"crossref","unstructured":"Kidney Disease: Improving Global Outcomes (KDIGO) (2024). CKD Work Group KDIGO 2024 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Int., 105, S117\u2013S314.","DOI":"10.1016\/j.kint.2023.10.018"},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1161\/hy09t1.094234","article-title":"Angiotensin II and Renal Fibrosis","volume":"38","author":"Mezzano","year":"2001","journal-title":"Hypertension"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11906-006-0009-8","article-title":"The Renin-Angiotensin System in Glomerular Podocytes: Mediator of Glomerulosclerosis and Link to Hypertensive Nephropathy","volume":"8","author":"Durvasula","year":"2006","journal-title":"Curr. Sci. Inc."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1016\/S0140-6736(18)32203-7","article-title":"Global, Regional, and National Age-Sex-Specific Mortality for 282 Causes of Death in 195 Countries and Territories, 1980\u20132017: A Systematic Analysis for the Global Burden of Disease Study 2017","volume":"392","author":"Roth","year":"2018","journal-title":"Lancet"},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1270","DOI":"10.1161\/CIRCULATIONAHA.115.016021","article-title":"Estimates of Global and Regional Premature Cardiovascular Mortality in 2025","volume":"132","author":"Roth","year":"2015","journal-title":"Circulation"},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1186\/1478-7954-8-9","article-title":"Algorithms for Enhancing Public Health Utility of National Causes-of-Death Data","volume":"8","author":"Naghavi","year":"2010","journal-title":"Popul Health Metrics"},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"3720","DOI":"10.1093\/eurheartj\/ehad191","article-title":"2023 ESC Guidelines for the Management of Acute Coronary Syndromes","volume":"44","author":"Byrne","year":"2023","journal-title":"Eur. Heart J."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1177\/174182679500200502","article-title":"Pathophysiological Aspects of the Renin-Angiotensin-Aldosterone System in Acute Myocardial Infarction","volume":"2","author":"Dargie","year":"1995","journal-title":"Eur. J. Cardiovasc. Prev. Rehabil."},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Yang, X., Li, Y., Li, Y., Ren, X., Zhang, X., Hu, D., Gao, Y., Xing, Y., and Shang, H. (2017). Oxidative Stress-Mediated Atherosclerosis: Mechanisms and Therapies. Front. Physiol., 8.","DOI":"10.3389\/fphys.2017.00600"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1161\/01.CIR.101.12.1372","article-title":"Expression of Angiotensin II and Interleukin 6 in Human Coronary Atherosclerotic Plaques: Potential Implications for Inflammation and Plaque Instability","volume":"101","author":"Schieffer","year":"2000","journal-title":"Circulation"},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"1973","DOI":"10.3892\/mmr.2017.6848","article-title":"The ACE2-Ang (1\u20137)-Mas Receptor Axis Attenuates Cardiac Remodeling and Fibrosis in Post-Myocardial Infarction","volume":"16","author":"Wang","year":"2017","journal-title":"Mol. Med. Rep."},{"key":"ref_172","first-page":"1852","article-title":"The Function of the ACE2\/Ang(1\u20137)\/Mas Receptor Axis of the Renin-Angiotensin System in Myocardial Ischemia Reperfusion Injury","volume":"26","author":"Xie","year":"2022","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_173","unstructured":"Evans-Lacko, S., Aguzzoli, E., Read, S., Comas-Herrera, A., and Farina, N. (2024). World Alzheimer Report 2024: Global Changes in Attitudes to Dementia, Alzheimer\u2019s Disease International."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"26208","DOI":"10.1021\/acsomega.5c00134","article-title":"New Prospects in the Inhibition of Monoamine Oxidase-B (MAO-B) Utilizing Propargylamine Derivatives for the Treatment of Alzheimer\u2019s Disease: A Review","volume":"10","author":"Chatzipieris","year":"2025","journal-title":"ACS Omega"},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/s41392-019-0063-8","article-title":"History and Progress of Hypotheses and Clinical Trials for Alzheimer\u2019s Disease","volume":"4","author":"Liu","year":"2019","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_176","doi-asserted-by":"crossref","unstructured":"Huang, L.-K., Chao, S.-P., and Hu, C.-J. (2020). Clinical Trials of New Drugs for Alzheimer Disease. J. Biomed. Sci., 27.","DOI":"10.1186\/s12929-019-0609-7"},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"101959","DOI":"10.1016\/j.arr.2023.101959","article-title":"Effects of Three Kinds of Anti-Amyloid-\u03b2 Drugs on Clinical, Biomarker, Neuroimaging Outcomes and Safety Indexes: A Systematic Review and Meta-Analysis of Phase II\/III Clinical Trials in Alzheimer\u2019s Disease","volume":"88","author":"Lyu","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"ref_178","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.neuron.2013.10.008","article-title":"The Pathobiology of Vascular Dementia","volume":"80","author":"Iadecola","year":"2013","journal-title":"Neuron"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1038\/nrn.2017.48","article-title":"Cerebral Blood Flow Regulation and Neurovascular Dysfunction in Alzheimer Disease","volume":"18","author":"Kisler","year":"2017","journal-title":"Nat. Rev. Neurosci."},{"key":"ref_180","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1007\/s11357-020-00231-y","article-title":"Brain Angiotensin II and Angiotensin IV Receptors as Potential Alzheimer\u2019s Disease Therapeutic Targets","volume":"42","author":"Royea","year":"2020","journal-title":"GeroScience"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1111\/fcp.12872","article-title":"Role of Angiotensin Receptor Blockers in the Context of Alzheimer\u2019s Disease","volume":"37","author":"Kuber","year":"2023","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"e062715","DOI":"10.1002\/alz.062715","article-title":"Treatment with Losartan, an AT1 Receptor Blocker, Improves Cognitive and Cardiovascular Function in a Dahl Salt-sensitive Rat Model of Age-associated Vascular Dementia","volume":"18","author":"Santos","year":"2022","journal-title":"Alzheimer\u2019s Dement."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"fcac270","DOI":"10.1093\/braincomms\/fcac270","article-title":"Safety and Biomarker Effects of Candesartan in Non-Hypertensive Adults with Prodromal Alzheimer\u2019s Disease","volume":"4","author":"Hajjar","year":"2022","journal-title":"Brain Commun."},{"key":"ref_184","doi-asserted-by":"crossref","unstructured":"Gebre, A.K., Altaye, B.M., Atey, T.M., Tuem, K.B., and Berhe, D.F. (2018). Targeting Renin\u2013Angiotensin System Against Alzheimer\u2019s Disease. Front. Pharmacol., 9.","DOI":"10.3389\/fphar.2018.00440"},{"key":"ref_185","doi-asserted-by":"crossref","unstructured":"Ababei, D.-C., Bild, V., Macadan, I., Vasincu, A., Rusu, R.-N., Blaj, M., Stanciu, G.D., Lefter, R.-M., and Bild, W. (2023). Therapeutic Implications of Renin-Angiotensin System Modulators in Alzheimer\u2019s Dementia. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15092290"},{"key":"ref_186","doi-asserted-by":"crossref","unstructured":"Cosarderelioglu, C., Nidadavolu, L.S., George, C.J., Oh, E.S., Bennett, D.A., Walston, J.D., and Abadir, P.M. (2020). Brain Renin\u2013Angiotensin System at the Intersect of Physical and Cognitive Frailty. Front. Neurosci., 14.","DOI":"10.3389\/fnins.2020.586314"},{"key":"ref_187","doi-asserted-by":"crossref","unstructured":"Cueto-Ure\u00f1a, C., Ram\u00edrez-Exp\u00f3sito, M.J., Carrera-Gonz\u00e1lez, M.P., and Mart\u00ednez-Martos, J.M. (2025). Physiopathology of the Brain Renin-Angiotensin System. Life, 15.","DOI":"10.3390\/life15081333"},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s12012-022-09730-0","article-title":"AT1 Receptors: Their Actions from Hypertension to Cognitive Impairment","volume":"22","author":"Wu","year":"2022","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1016\/S0140-6736(21)00218-X","article-title":"Parkinson\u2019s Disease","volume":"397","author":"Bloem","year":"2021","journal-title":"Lancet"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.4103\/1673-5374.313061","article-title":"Potential Protective Role of ACE-Inhibitors and AT1 Receptor Blockers against Levodopa-Induced Dyskinesias: A Retrospective Case-Control Study","volume":"16","author":"Contaldi","year":"2021","journal-title":"Neural Regen. Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1080\/13543784.2017.1371133","article-title":"Renin-Angiotensin System as a Potential Target for New Therapeutic Approaches in Parkinson\u2019s Disease","volume":"26","author":"Toblli","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.parkreldis.2021.03.007","article-title":"Effects of Angiotensin Type 1 Receptor Antagonists on Parkinson\u2019s Disease Progression: An Exploratory Study in the PPMI Database","volume":"86","author":"Udovin","year":"2021","journal-title":"Park. Relat. Disord."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1007\/s11064-015-1536-y","article-title":"Angiotensin II Triggers Apoptosis Via Enhancement of NADPH Oxidase-Dependent Oxidative Stress in a Dopaminergic Neuronal Cell Line","volume":"40","author":"Zhao","year":"2015","journal-title":"Neurochem. Res."},{"key":"ref_194","doi-asserted-by":"crossref","unstructured":"Kobiec, T., Otero-Losada, M., Chevalier, G., Udovin, L., Bordet, S., Men\u00e9ndez-Maissonave, C., Capani, F., and P\u00e9rez-Lloret, S. (2021). The Renin\u2013Angiotensin System Modulates Dopaminergic Neurotransmission: A New Player on the Scene. Front. Synaptic Neurosci., 13.","DOI":"10.3389\/fnsyn.2021.638519"},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1186\/s40035-024-00410-3","article-title":"The Role of the Brain Renin-Angiotensin System in Parkinson\u2019s Disease","volume":"13","author":"Labandeira","year":"2024","journal-title":"Transl. Neurodegener."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e01083","DOI":"10.1002\/prp2.1083","article-title":"Telmisartan and Losartan: The Marked Differences between Their Chemical and Pharmacological Properties May Explain the Difference in Therapeutic Efficacy in Hospitalized Patients with COVID-19","volume":"11","author":"Rothlin","year":"2023","journal-title":"Pharmacol. Res. Perspect."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.fjps.2017.04.001","article-title":"Olmesartan Medoxomil-Loaded Mixed Micelles: Preparation, Characterization and in-Vitro Evaluation","volume":"3","author":"Tadros","year":"2017","journal-title":"Future J. Pharm. Sci."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.biopha.2017.01.164","article-title":"Pharmacodynamic Study of Eprosartan Mesylate-Loaded Transfersomes Carbopol\u00ae Gel under Dermaroller\u00ae on Rats with Methyl Prednisolone Acetate-Induced Hypertension","volume":"89","author":"Ahad","year":"2017","journal-title":"Biomed. Pharmacother."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/bs.podrm.2020.07.004","article-title":"Irbesartan (a Comprehensive Profile)","volume":"Volume 46","author":"Darwish","year":"2021","journal-title":"Profiles of Drug Substances, Excipients and Related Methodology"},{"key":"ref_200","first-page":"100281","article-title":"Key Determinants of the Chemo-Sensitizing Activity of Novel Telmisartan Derivatives","volume":"15","author":"Gebhart","year":"2025","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"ref_201","doi-asserted-by":"crossref","unstructured":"Anwar, W., Dawaba, H., Afouna, M., Samy, A., Rashed, M., and Abdelaziz, A. (2020). Enhancing the Oral Bioavailability of Candesartan Cilexetil Loaded Nanostructured Lipid Carriers: In Vitro Characterization and Absorption in Rats after Oral Administration. Pharmaceutics, 12.","DOI":"10.3390\/pharmaceutics12111047"},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1161\/HYPERTENSIONAHA.121.17595","article-title":"Blood-Brain Barrier Crossing Renin-Angiotensin System Drugs: Considerations for Dementia and Cognitive Decline","volume":"78","author":"Glodzik","year":"2021","journal-title":"Hypertension"},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1161\/HYPERTENSIONAHA.121.17049","article-title":"Blood-Brain Barrier Crossing Renin-Angiotensin Drugs and Cognition in the Elderly: A Meta-Analysis","volume":"78","author":"Ho","year":"2021","journal-title":"Hypertension"},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/mdc3.14326","article-title":"An Open-Label, Non-randomized, Drug-Repurposing Study to Explore the Clinical Effects of Angiotensin II Type 1 (AT1) Receptor Antagonists on Anxiety and Depression in Parkinson\u2019s Disease","volume":"12","author":"Bordet","year":"2025","journal-title":"Mov. Disord. Clin. Pract."},{"key":"ref_205","doi-asserted-by":"crossref","first-page":"105354","DOI":"10.1016\/j.psyneuen.2021.105354","article-title":"The Association between the Renin-Angiotensin System and the Hypothalamic-Pituitary-Adrenal Axis in Anxiety Disorders: A Systematic Review of Animal Studies","volume":"132","author":"Balthazar","year":"2021","journal-title":"Psychoneuroendocrinology"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1210\/en.2006-0198","article-title":"Angiotensin II Inhibition Reduces Stress Sensitivity of Hypothalamo-Pituitary-Adrenal Axis in Spontaneously Hypertensive Rats","volume":"147","author":"Raasch","year":"2006","journal-title":"Endocrinology"},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1007\/978-1-4757-3538-3_74","article-title":"The Role of Angiotensin II AT1 Receptors in the Sympathoadrenal Response to Stress","volume":"Volume 53","author":"Nagatsu","year":"2002","journal-title":"Catecholamine Research"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"27","DOI":"10.55627\/pmc.003.01.0296","article-title":"Biomarker-Guided Drug Repurposing and Molecular Validation of Angiotensin-2 Receptor Type-1 in Brain Tumor","volume":"3","author":"Konain","year":"2023","journal-title":"Precis. Med. Commun."},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jocn.2021.11.023","article-title":"Treatment of Glioblastoma with Re-Purposed Renin-Angiotensin System Modulators: Results of a Phase I Clinical Trial","volume":"95","author":"Wickremesekera","year":"2022","journal-title":"J. Clin. Neurosci."},{"key":"ref_210","doi-asserted-by":"crossref","unstructured":"Ridgway, H., Chasapis, C.T., Kelaidonis, K., Ligielli, I., Moore, G.J., Gadanec, L.K., Zulli, A., Apostolopoulos, V., Mavromoustakos, T., and Matsoukas, J.M. (2022). Understanding the Driving Forces That Trigger Mutations in SARS-CoV-2: Mutational Energetics and the Role of Arginine Blockers in COVID-19 Therapy. Viruses, 14.","DOI":"10.3390\/v14051029"},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"e142137","DOI":"10.1172\/JCI142137","article-title":"Arginine Deprivation Alters Microglial Polarity and Synergizes with Radiation to Eradicate Non-Arginine-Auxotrophic Glioblastoma Tumors","volume":"132","author":"Hajji","year":"2022","journal-title":"J. Clin. Investig."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.2116289119","article-title":"Inhibition of the Angiotensin II Type 2 Receptor AT2R Is a Novel Therapeutic Strategy for Glioblastoma","volume":"119","author":"Perryman","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"1978","DOI":"10.1021\/acs.jmedchem.9b01780","article-title":"The Other Angiotensin II Receptor: AT2R as a Therapeutic Target","volume":"63","year":"2020","journal-title":"J. Med. Chem."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1038\/sj.bjc.6604431","article-title":"Expression of AT1 and AT2 Angiotensin Receptors in Astrocytomas Is Associated with Poor Prognosis","volume":"99","author":"Arrieta","year":"2008","journal-title":"Br. J. Cancer"},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1007\/s12253-018-0471-z","article-title":"Suppression of Angiotensin-(1\u20137) on the Disruption of Blood-Brain Barrier in Rat of Brain Glioma","volume":"25","author":"Li","year":"2019","journal-title":"Pathol. Oncol. Res."},{"key":"ref_216","doi-asserted-by":"crossref","unstructured":"Lin, W.-Y., Li, L.-H., Hsiao, Y.-Y., Wong, W.-T., Chiu, H.-W., Hsu, H.-T., Peng, Y.-J., Ho, C.-L., Chernikov, O.V., and Cheng, S.-M. (2022). Repositioning of the Angiotensin II Receptor Antagonist Candesartan as an Anti-Inflammatory Agent With NLRP3 Inflammasome Inhibitory Activity. Front. Immunol., 13.","DOI":"10.3389\/fimmu.2022.870627"},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.mayocp.2022.06.036","article-title":"Effect of the Renin-Angiotensin System Inhibitors on Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Controlled Trials","volume":"97","author":"Awad","year":"2022","journal-title":"Mayo Clin. Proc."},{"key":"ref_218","doi-asserted-by":"crossref","first-page":"14942","DOI":"10.1073\/pnas.0903602106","article-title":"Role of the Renin-Angiotensin System in Autoimmune Inflammation of the Central Nervous System","volume":"106","author":"Stegbauer","year":"2009","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_219","doi-asserted-by":"crossref","unstructured":"Haliga, R.E., Cojocaru, E., S\u00eerbu, O., Hri\u021bcu, I., Alexa, R.E., Haliga, I.B., \u0218orodoc, V., and Coman, A.E. (2025). Immunomodulatory Effects of RAAS Inhibitors: Beyond Hypertension and Heart Failure. Biomedicines, 13.","DOI":"10.3390\/biomedicines13071779"},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"7834","DOI":"10.1021\/jm800891n","article-title":"Citrullination of Linear and Cyclic Altered Peptide Ligands from Myelin Basic Protein (MBP87\u221299) Epitope Elicits a Th1 Polarized Response by T Cells Isolated from Multiple Sclerosis Patients: Implications in Triggering Disease","volume":"51","author":"Deraos","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.2174\/0929867054039053","article-title":"Structural Requirements for Binding of Myelin Basic Protein (MBP) Peptides to MHC II: Effects on Immune Regulation","volume":"12","author":"Mantzourani","year":"2005","journal-title":"Curr. Med. Chem."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"2091","DOI":"10.1016\/j.csbj.2022.04.010","article-title":"Discovery of a New Generation of Angiotensin Receptor Blocking Drugs: Receptor Mechanisms and in Silico Binding to Enzymes Relevant to SARS-CoV-2","volume":"20","author":"Ridgway","year":"2022","journal-title":"Comput. Struct. Biotechnol. J."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1089\/adt.2023.013","article-title":"Losartan Plays a Fungistatic and Fungicidal Activity Against Candida Albicans Biofilms: Drug Repurposing for Localized Candidosis","volume":"21","author":"Lara","year":"2023","journal-title":"ASSAY Drug Dev. Technol."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"e13280","DOI":"10.1111\/apha.13280","article-title":"Anti-fibrotic Mechanisms of Angiotensin AT2-receptor Stimulation","volume":"227","author":"Sumners","year":"2019","journal-title":"Acta Physiol."},{"key":"ref_225","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s13069-015-0023-z","article-title":"Modulation of Angiotensin II Signaling in the Prevention of Fibrosis","volume":"8","author":"Murphy","year":"2015","journal-title":"Fibrogenesis Tissue Repair"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"134","DOI":"10.4172\/2576-1471.1000134","article-title":"Angiotensin-(1\u20137) and the Regulation of Anti-Fibrotic Signaling Pathways","volume":"2","author":"Chappell","year":"2017","journal-title":"J. Cell Signal"},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"110935","DOI":"10.1016\/j.cellsig.2023.110935","article-title":"Angiotensin II Type-2 Receptor Attenuates Liver Fibrosis Progression by Suppressing IRE1\u03b1-XBP1 Pathway","volume":"113","author":"An","year":"2024","journal-title":"Cell. Signal."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1111\/j.1478-3231.2009.01973.x","article-title":"The Effect of Angiotensin-blocking Agents on Liver Fibrosis in Patients with Hepatitis C","volume":"29","author":"Corey","year":"2009","journal-title":"Liver Int."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/art.11364","article-title":"Angiotensin II in the Lesional Skin of Systemic Sclerosis Patients Contributes to Tissue Fibrosis via Angiotensin II Type 1 Receptors","volume":"50","author":"Kawaguchi","year":"2004","journal-title":"Arthritis Rheum."},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1002\/1529-0131(199912)42:12<2646::AID-ANR21>3.0.CO;2-T","article-title":"Losartan Therapy for Raynaud\u2019s Phenomenon and Scleroderma: Clinical and Biochemical Findings in a Fifteen-Week, Randomized, Parallel-Group, Controlled Trial","volume":"42","author":"Dziadzio","year":"1999","journal-title":"Arthritis Rheum."},{"key":"ref_231","doi-asserted-by":"crossref","unstructured":"Iwane, S., Nemoto, W., Miyamoto, T., Hayashi, T., Tanaka, M., Uchitani, K., Muranaka, T., Fujitani, M., Koizumi, Y., and Hirata, A. (2024). Clinical and Preclinical Evidence That Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers Prevent Diabetic Peripheral Neuropathy. Sci. Rep., 14.","DOI":"10.1038\/s41598-024-51572-z"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1124\/mol.116.104133","article-title":"Involvement of Spinal Angiotensin II System in Streptozotocin-Induced Diabetic Neuropathic Pain in Mice","volume":"90","author":"Ogata","year":"2016","journal-title":"Mol. Pharmacol."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1007\/BF00400799","article-title":"Angiotensin II Receptor Blockade Improves Nerve Function, Modulates Nerve Blood Flow and Stimulates Endoneurial Angiogenesis in Streptozotocin-Diabetic Ratsand Nerve Function","volume":"36","author":"Maxfield","year":"1993","journal-title":"Diabetologia"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1089\/ars.2012.4604","article-title":"Angiotensin II-Induced Production of Mitochondrial Reactive Oxygen Species: Potential Mechanisms and Relevance for Cardiovascular Disease","volume":"19","author":"Dikalov","year":"2013","journal-title":"Antioxid. Redox Signal."},{"key":"ref_235","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/bcpt.13624","article-title":"Renin\u2013Angiotensin System in Intestinal Inflammation\u2014Angiotensin Inhibitors to Treat Inflammatory Bowel Diseases?","volume":"129","author":"Salmenkari","year":"2021","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"G774","DOI":"10.1152\/ajpgi.00053.2019","article-title":"Renin-Angiotensin System Promotes Colonic Inflammation by Inducing TH17 Activation via JAK2\/STAT Pathway","volume":"316","author":"He","year":"2019","journal-title":"Am. J. Physiol. Gastrointest. Liver Physiol."},{"key":"ref_237","doi-asserted-by":"crossref","unstructured":"Khajah, M.A., Fateel, M.M., Ananthalakshmi, K.V., and Luqmani, Y.A. (2016). Anti-Inflammatory Action of Angiotensin 1\u20137 in Experimental Colitis. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0150861"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1007\/s10620-019-5474-4","article-title":"Impact of Angiotensin II Signaling Blockade on Clinical Outcomes in Patients with Inflammatory Bowel Disease","volume":"64","author":"Jacobs","year":"2019","journal-title":"Dig. Dis. Sci."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1016\/S0140-6736(22)01534-3","article-title":"Angiotensin Receptor Blockers and \u03b2 Blockers in Marfan Syndrome: An Individual Patient Data Meta-Analysis of Randomised Trials","volume":"400","author":"Pitcher","year":"2022","journal-title":"Lancet"},{"key":"ref_240","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1126\/science.1124287","article-title":"Losartan, an AT1 Antagonist, Prevents Aortic Aneurysm in a Mouse Model of Marfan Syndrome","volume":"312","author":"Habashi","year":"2006","journal-title":"Science"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1126\/science.1192152","article-title":"Angiotensin II Type 2 Receptor Signaling Attenuates Aortic Aneurysm in Mice Through ERK Antagonism","volume":"332","author":"Habashi","year":"2011","journal-title":"Science"},{"key":"ref_242","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1038\/nm1536","article-title":"Angiotensin II Type 1 Receptor Blockade Attenuates TGF-\u03b2\u2013Induced Failure of Muscle Regeneration in Multiple Myopathic States","volume":"13","author":"Cohn","year":"2007","journal-title":"Nat. Med."},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Asano, K., Cantalupo, A., Sedes, L., and Ramirez, F. (2022). Pathophysiology and Therapeutics of Thoracic Aortic Aneurysm in Marfan Syndrome. Biomolecules, 12.","DOI":"10.3390\/biom12010128"},{"key":"ref_244","doi-asserted-by":"crossref","unstructured":"Matsoukas, J., Apostolopoulos, V., Zulli, A., Moore, G., Kelaidonis, K., Moschovou, K., and Mavromoustakos, T. (2021). From Angiotensin II to Cyclic Peptides and Angiotensin Receptor Blockers (ARBs): Perspectives of ARBs in COVID-19 Therapy. Molecules, 26.","DOI":"10.3390\/molecules26030618"},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"e072175","DOI":"10.1136\/bmj-2022-072175","article-title":"Angiotensin Receptor Blockers for the Treatment of COVID-19: Pragmatic, Adaptive, Multicentre, Phase 3, Randomised Controlled Trial","volume":"379","author":"Jardine","year":"2022","journal-title":"BMJ"},{"key":"ref_246","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1186\/s13613-024-01369-0","article-title":"Angiotensin-(1\u20137) Infusion in COVID-19 Patients Admitted to the ICU: A Seamless Phase 1\u20132 Randomized Clinical Trial","volume":"14","author":"Martins","year":"2024","journal-title":"Ann. Intensive Care"},{"key":"ref_247","doi-asserted-by":"crossref","first-page":"6619","DOI":"10.1007\/s11033-021-06672-8","article-title":"The Role of Renin Angiotensin System in the Pathophysiology of Rheumatoid Arthritis","volume":"48","author":"Moreira","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"ref_248","doi-asserted-by":"crossref","unstructured":"Kaur, B., Singh, H., Choudhary, G., Prakash, A., Medhi, B., Chatterjee, D., Saini, U.C., Kaur, J., Verma, I., and Sharma, S. (2025). Natural Angiotensin II Type 1 Receptor Inhibitors: Virtual Screening and in Vitro Evaluation of Beta-1,2,3,4,6-Penta-O-Galloyl-d-Glucopyranose, Icarrin, and Sesamin for Osteoarthritis Therapy. Int. J. Biol. Macromol., 309.","DOI":"10.1016\/j.ijbiomac.2025.142184"},{"key":"ref_249","doi-asserted-by":"crossref","unstructured":"Guo, Z., Di, J., Zhang, Z., Chen, S., Mao, X., Wang, Z., Yan, Z., Li, X., Tian, Z., and Mu, C. (2024). Antihypertensive Drug-Associated Adverse Events in Osteoarthritis: A Study of a Large Real-World Sample Based on the FAERS Database. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1404427"},{"key":"ref_250","unstructured":"Substance Abuse and Mental Health Services Administration (2020). Key Substance Use and Mental Health Indicators in the United States: Results from the 2019 National Survey on Drug Use and Health, Center for Behavioral Health Statistics and Quality, Substance Abuse and Mental Health Services."},{"key":"ref_251","doi-asserted-by":"crossref","first-page":"S10","DOI":"10.1002\/jcph.1937","article-title":"The Epidemiology of Drug Abuse","volume":"61","author":"Ignaszewski","year":"2021","journal-title":"J. Clin. Pharmacol."},{"key":"ref_252","doi-asserted-by":"crossref","unstructured":"Ridgway, H., Moore, G.J., Gadanec, L.K., and Matsoukas, J.M. (2025). Docking Simulations of G-Protein Coupled Receptors Uncover Crossover Binding Patterns of Diverse Ligands to Angiotensin, Alpha-Adrenergic and Opioid Receptors: Implications for Cardiovascular Disease and Addiction. Biomolecules, 15.","DOI":"10.3390\/biom15060855"},{"key":"ref_253","doi-asserted-by":"crossref","first-page":"223","DOI":"10.2147\/VHRM.S2446","article-title":"Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) and Resource Utilization and Costs in Italy","volume":"4","author":"Colombo","year":"2008","journal-title":"Vasc. Health Risk Manag."},{"key":"ref_254","doi-asserted-by":"crossref","first-page":"2454","DOI":"10.1161\/01.CIR.0000036747.68104.AC","article-title":"Effects of Valsartan on Circulating Brain Natriuretic Peptide and Norepinephrine in Symptomatic Chronic Heart Failure: The Valsartan Heart Failure Trial (Val-HeFT)","volume":"106","author":"Latini","year":"2002","journal-title":"Circulation"},{"key":"ref_255","doi-asserted-by":"crossref","first-page":"19","DOI":"10.2337\/diaclin.20.1.19","article-title":"The RENAAL Study Investigation","volume":"20","author":"Sharma","year":"2002","journal-title":"Clin. Diabetes"},{"key":"ref_256","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective Effect of the Angiotensin-Receptor Antagonist Irbesartan in Patients with Nephropathy Due to Type 2 Diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N. Engl. J. Med."},{"key":"ref_257","doi-asserted-by":"crossref","unstructured":"The ONTARGET Investigators (2008). Telmisartan, Ramipril, or Both in Patients at High Risk for Vascular Events. N. Engl. J. Med., 358, 1547\u20131559.","DOI":"10.1056\/NEJMoa0801317"},{"key":"ref_258","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, Captopril, or Both in Myocardial Infarction Complicated by Heart Failure, Left Ventricular Dysfunction, or Both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_259","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0140-6736(02)09895-1","article-title":"Effects of Losartan and Captopril on Mortality and Morbidity in High-Risk Patients after Acute Myocardial Infarction: The OPTIMAAL Randomised Trial","volume":"360","author":"Dickstein","year":"2002","journal-title":"Lancet"},{"key":"ref_260","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1536\/ihj.47.715","article-title":"Inhibitory Effect of Candesartan Cilexetil on Left Ventricular Remodeling After Myocardial Infarction","volume":"47","author":"Suzuki","year":"2006","journal-title":"Int. Heart J."},{"key":"ref_261","first-page":"e69798","article-title":"Evaluation of Anxiolytic Activity of Angiotensin Receptor Blockers Using Actophotometer Test in Wistar Rats","volume":"16","author":"Thorat","year":"2024","journal-title":"Cureus"},{"key":"ref_262","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1073\/pnas.2219199120","article-title":"Losartan Controls Immune Checkpoint Blocker-Induced Edema and Improves Survival in Glioblastoma Mouse Models","volume":"120","author":"Datta","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_263","doi-asserted-by":"crossref","first-page":"3957","DOI":"10.1007\/s00284-021-02663-x","article-title":"Impeding Virulence of Candida Albicans by Candesartan and Domperidone","volume":"78","author":"Abbas","year":"2021","journal-title":"Curr. Microbiol."},{"key":"ref_264","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1007\/s00408-012-9410-z","article-title":"Treatment of Idiopathic Pulmonary Fibrosis with Losartan: A Pilot Project","volume":"190","author":"Couluris","year":"2012","journal-title":"Lung"},{"key":"ref_265","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/1756-3305-6-199","article-title":"Telmisartan, an AT1 Receptor Blocker and a PPAR Gamma Activator, Alleviates Liver Fibrosis Induced Experimentally by Schistosoma Mansoni Infection","volume":"6","author":"Attia","year":"2013","journal-title":"Parasit. Vectors"},{"key":"ref_266","doi-asserted-by":"crossref","first-page":"100654","DOI":"10.1016\/j.curtheres.2021.100654","article-title":"Effect of Candesartan and Ramipril on Liver Fibrosis in Patients with Chronic Hepatitis C Viral Infection: A Randomized Controlled Prospective Study","volume":"95","author":"Mostafa","year":"2021","journal-title":"Curr. Ther. Res. Clin. Exp."},{"key":"ref_267","doi-asserted-by":"crossref","first-page":"603","DOI":"10.2147\/DDDT.S224308","article-title":"Silibinin Augments the Antifibrotic Effect of Valsartan Through Inactivation of TGF-\u03921 Signaling in Kidney","volume":"14","author":"Liu","year":"2020","journal-title":"Drug Des. Devel Ther."},{"key":"ref_268","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1055\/s-0035-1550019","article-title":"The Protective Effect of Losartan on Diabetic Neuropathy in a Diabetic Rat Model","volume":"123","author":"Cavusoglu","year":"2015","journal-title":"Exp. Clin. Endocrinol. Diabetes"},{"key":"ref_269","doi-asserted-by":"crossref","first-page":"115","DOI":"10.17712\/nsj.2015.2.20140511","article-title":"Telmisartan Inhibits Hyperalgesia and Inflammatory Progression in a Diabetic Neuropathic Pain Model of Wistar Rats","volume":"20","author":"Abuohashish","year":"2015","journal-title":"Neurosciences"},{"key":"ref_270","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1155\/2012\/628268","article-title":"Losartan Reduces Trinitrobenzene Sulphonic Acid-Induced Colorectal Fibrosis in Rats","volume":"26","author":"Wengrower","year":"2012","journal-title":"Can. J. Gastroenterol."},{"key":"ref_271","doi-asserted-by":"crossref","unstructured":"Arab, H.H., Al-Shorbagy, M.Y., Abdallah, D.M., and Nassar, N.N. (2014). Telmisartan Attenuates Colon Inflammation, Oxidative Perturbations and Apoptosis in a Rat Model of Experimental Inflammatory Bowel Disease. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0097193"},{"key":"ref_272","doi-asserted-by":"crossref","first-page":"S12","DOI":"10.1016\/j.jamcollsurg.2010.06.026","article-title":"Blockade of Angiotensin II Type 1a Receptor in a DSS Model of Colitis Results in Significant Expansion of Foxp3 Regulatory T Cells","volume":"211","author":"Okawada","year":"2010","journal-title":"J. Am. Coll. Surg."},{"key":"ref_273","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.regpep.2007.10.004","article-title":"An Angiotensin II Receptor Antagonist Reduces Inflammatory Parameters in Two Models of Colitis","volume":"146","author":"Santiago","year":"2008","journal-title":"Regul. Pept."},{"key":"ref_274","doi-asserted-by":"crossref","first-page":"3491","DOI":"10.1093\/eurheartj\/eht334","article-title":"Losartan Reduces Aortic Dilatation Rate in Adults with Marfan Syndrome: A Randomized Controlled Trial","volume":"34","author":"Groenink","year":"2013","journal-title":"Eur. Heart J."},{"key":"ref_275","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1016\/S0140-6736(19)32536-X","article-title":"Angiotensin-II Receptor Blockade in Marfan Syndrome","volume":"394","year":"2019","journal-title":"Lancet"},{"key":"ref_276","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.ijcard.2012.03.051","article-title":"An Evidence-Based Hypothesis for Beneficial Effects of Telmisartan on Marfan Syndrome","volume":"158","author":"Takagi","year":"2012","journal-title":"Int. J. Cardiol."},{"key":"ref_277","doi-asserted-by":"crossref","first-page":"100962","DOI":"10.1016\/j.eclinm.2021.100962","article-title":"Telmisartan for Treatment of COVID-19 Patients: An Open Multicenter Randomized Clinical Trial","volume":"37","author":"Duarte","year":"2021","journal-title":"eClinicalMedicine"},{"key":"ref_278","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1042\/CS20201511","article-title":"Experimental Data Using Candesartan and Captopril Indicate No Double-Edged Sword Effect in COVID-19","volume":"135","author":"Pedrosa","year":"2021","journal-title":"Clin. Sci."},{"key":"ref_279","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1007\/s10787-018-0545-2","article-title":"Losartan Suppresses the Inflammatory Response in Collagen-Induced Arthritis by Inhibiting the MAPK and NF-\u03baB Pathways in B and T Cells","volume":"27","author":"Wang","year":"2019","journal-title":"Inflammopharmacol"},{"key":"ref_280","doi-asserted-by":"crossref","first-page":"1920","DOI":"10.1002\/art.21040","article-title":"Angiotensin Receptor Blockers Suppress Antigen-specific T Cell Responses and Ameliorate Collagen-induced Arthritis in Mice","volume":"52","author":"Sagawa","year":"2005","journal-title":"Arthritis Rheum."},{"key":"ref_281","first-page":"30","article-title":"Losartan Protects against Osteoarthritis by Repressing the TGF-\u03921 Signaling Pathway via Upregulation of PPAR\u03b3","volume":"29","author":"Deng","year":"2021","journal-title":"J. Orthop. Transl."},{"key":"ref_282","doi-asserted-by":"crossref","unstructured":"Kar\u00e1di, D.\u00c1., Galambos, A.R., Lakatos, P.P., Apenberg, J., Abbood, S.K., Balogh, M., Kir\u00e1ly, K., Riba, P., Essmat, N., and Sz\u0171cs, E. (2023). Telmisartan Is a Promising Agent for Managing Neuropathic Pain and Delaying Opioid Analgesic Tolerance in Rats. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24097970"},{"key":"ref_283","doi-asserted-by":"crossref","first-page":"318","DOI":"10.3892\/mmr.2022.12834","article-title":"Angiotensin II Receptor Type 1 Blocker Candesartan Improves Morphine Tolerance by Reducing Morphine-induced Inflammatory Response and Cellular Activation of BV2 Cells via the PPAR\u03b3\/AMPK Signaling Pathway","volume":"26","author":"Zhao","year":"2022","journal-title":"Mol. Med. Rep."},{"key":"ref_284","doi-asserted-by":"crossref","first-page":"1737","DOI":"10.1016\/S0960-894X(03)00251-8","article-title":"Design and Synthesis of Novel Antihypertensive Drugs","volume":"13","author":"Gianni","year":"2003","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_285","doi-asserted-by":"crossref","first-page":"4353","DOI":"10.1016\/j.bmc.2006.02.044","article-title":"Synthesis, Binding Studies and in Vivo Biological Evaluation of Novel Non-Peptide Antihypertensive Analogues","volume":"14","author":"Mavromoustakos","year":"2006","journal-title":"Bioorganic Med. Chem."},{"key":"ref_286","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1016\/j.jpba.2005.09.016","article-title":"Structure Elucidation and Conformational Study of V8","volume":"40","author":"Zoumpoulakis","year":"2006","journal-title":"J. Pharm. Biomed. Anal."},{"key":"ref_287","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1007\/s10822-010-9371-3","article-title":"An Efficient Synthesis of a Rationally Designed 1,5 Disubstituted Imidazole AT1 Angiotensin II Receptor Antagonist: Reorientation of Imidazole Pharmacophore Groups in Losartan Reserves High Receptor Affinity and Confirms Docking Studies","volume":"24","author":"Agelis","year":"2010","journal-title":"J. Comput. Aided Mol. Des."},{"key":"ref_288","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1016\/j.ejmech.2012.07.040","article-title":"The Discovery of New Potent Non-Peptide Angiotensin II AT1 Receptor Blockers: A Concise Synthesis, Molecular Docking Studies and Biological Evaluation of N-Substituted 5-Butylimidazole Derivatives","volume":"55","author":"Agelis","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"ref_289","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1016\/j.bbamem.2013.03.009","article-title":"Interactions of the Potent Synthetic AT1 Antagonist Analog BV6 with Membrane Bilayers and Mesoporous Silicate Matrices","volume":"1828","author":"Agelis","year":"2013","journal-title":"Biochim. Et. Biophys. Acta (BBA)\u2014Biomembr."},{"key":"ref_290","doi-asserted-by":"crossref","unstructured":"Moore, G.J., Ridgway, H., Kelaidonis, K., Chasapis, C.T., Ligielli, I., Mavromoustakos, T., Bojarska, J., and Matsoukas, J.M. (2022). Actions of Novel Angiotensin Receptor Blocking Drugs, Bisartans, Relevant for COVID-19 Therapy: Biased Agonism at Angiotensin Receptors and the Beneficial Effects of Neprilysin in the Renin Angiotensin System. Molecules, 27.","DOI":"10.3390\/molecules27154854"},{"key":"ref_291","doi-asserted-by":"crossref","unstructured":"Kelaidonis, K., Ligielli, I., Letsios, S., Vidali, V.P., Mavromoustakos, T., Vassilaki, N., Moore, G.J., Hoffmann, W., W\u0119grzyn, K., and Ridgway, H. (2023). Computational and Enzymatic Studies of Sartans in SARS-CoV-2 Spike RBD-ACE2 Binding: The Role of Tetrazole and Perspectives as Antihypertensive and COVID-19 Therapeutics. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24098454"},{"key":"ref_292","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.ejmech.2012.12.044","article-title":"Rational Design, Efficient Syntheses and Biological Evaluation of N, N\u2032-Symmetrically Bis-Substituted Butylimidazole Analogs as a New Class of Potent Angiotensin II Receptor Blockers","volume":"62","author":"Agelis","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"ref_293","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.freeradbiomed.2020.08.007","article-title":"Enhancement of Glioblastoma Multiforme Therapy through a Novel Quercetin-Losartan Hybrid","volume":"160","author":"Tsiailanis","year":"2020","journal-title":"Free Radic. Biol. Med."},{"key":"ref_294","doi-asserted-by":"crossref","first-page":"13889","DOI":"10.1080\/07391102.2021.1996461","article-title":"Development of a DHA-Losartan Hybrid as a Potent Inhibitor of Multiple Pathway-Induced Platelet Aggregation","volume":"40","author":"Tsiailanis","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"ref_295","doi-asserted-by":"crossref","unstructured":"Georgiou, N., Gkalpinos, V.K., Katsakos, S.D., Vassiliou, S., Tzakos, A.G., and Mavromoustakos, T. (2021). Rational Design and Synthesis of AT1R Antagonists. Molecules, 26.","DOI":"10.3390\/molecules26102927"},{"key":"ref_296","doi-asserted-by":"crossref","first-page":"4444","DOI":"10.1016\/j.bmc.2016.07.047","article-title":"Exploring New Scaffolds for Angiotensin II Receptor Antagonism","volume":"24","author":"Kritsi","year":"2016","journal-title":"Bioorganic Med. Chem."},{"key":"ref_297","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1472-8206.2002.00076.x","article-title":"Binding of KRH-594, an Antagonist of the Angiotensin II Type 1 Receptor, to Cloned Human and Rat Angiotensin II Receptors","volume":"16","author":"Inada","year":"2002","journal-title":"Fundam. Clin. Pharmacol."},{"key":"ref_298","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1016\/S0960-894X(96)00250-8","article-title":"Acyliminothiadiazoline Derivatives: New, Highly Potent, and Orally Active Angiotensin II Receptor Antagonists","volume":"6","author":"Hirata","year":"1996","journal-title":"Bioorganic Med. Chem. Lett."},{"key":"ref_299","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/00005344-199711000-00011","article-title":"Pharmacologic Profiles of KRH-594, a Novel Nonpeptide Angiotensin II-Receptor Antagonist","volume":"30","author":"Tamura","year":"1997","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"ref_300","unstructured":"Kotobuki, P. Unpublished Data Held on File, (Kotobuki Research Laboratories, Kotobuki Seiyaku Company, Ltd., Kawagoe, Japan)."},{"key":"ref_301","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1046\/j.1365-2125.2003.01932.x","article-title":"The Effects of KT3-671, a New Angiotensin II (AT 1) Receptor Blocker in Mild to Moderate Hypertension","volume":"56","author":"Patterson","year":"2003","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_302","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ejmech.2015.09.010","article-title":"Discovery of Novel, Potent and Low-Toxicity Angiotensin II Receptor Type 1 (AT1) Blockers: Design, Synthesis and Biological Evaluation of 6-Substituted Aminocarbonyl Benzimidazoles with a Chiral Center","volume":"103","author":"Han","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_303","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.ejmech.2016.03.021","article-title":"N-Phenyl Indole Derivatives as AT1 Antagonists with Anti-Hypertension Activities: Design, Synthesis and Biological Evaluation","volume":"115","author":"Zhu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_304","doi-asserted-by":"crossref","first-page":"435","DOI":"10.3109\/10641963.2016.1151527","article-title":"Design, Synthesis, and Pharmacological Evaluation of 5-Oxo-1,2,4-Oxadiazole Derivatives as AT1 Antagonists with Antihypertension Activities","volume":"38","author":"Zhu","year":"2016","journal-title":"Clin. Exp. Hypertens."},{"key":"ref_305","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1021\/acs.chemrestox.4c00368","article-title":"Design, Synthesis, and Biological Evaluation of New Oxadiazole Derivatives as Efficient Antihypertension Drugs","volume":"38","author":"Qu","year":"2025","journal-title":"Chem. Res. Toxicol."},{"key":"ref_306","doi-asserted-by":"crossref","first-page":"1987","DOI":"10.18520\/cs\/v116\/i12\/1987-1992","article-title":"Pharmacological Evaluation on Antihypertensive Activity of a Novel AT1 Angiotensin II Receptor Antagonist","volume":"116","author":"Tang","year":"2019","journal-title":"Curr. Sci."},{"key":"ref_307","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/j.bmc.2014.02.008","article-title":"Design, Synthesis and Biological Evaluation of New 5-Nitro Benzimidazole Derivatives as AT1 Antagonists with Anti-Hypertension Activities","volume":"22","author":"Zhu","year":"2014","journal-title":"Bioorganic Med. Chem."},{"key":"ref_308","doi-asserted-by":"crossref","unstructured":"Ridgway, H., Apostolopoulos, V., Moore, G.J., Gadanec, L.K., Zulli, A., Swiderski, J., Tsiodras, S., Kelaidonis, K., Chasapis, C.T., and Matsoukas, J.M. (2024). Computational Evidence for Bisartan Arginine Blockers as Next-Generation Pan-Antiviral Therapeutics Targeting SARS-CoV-2, Influenza, and Respiratory Syncytial Viruses. Viruses, 16.","DOI":"10.3390\/v16111776"},{"key":"ref_309","doi-asserted-by":"crossref","unstructured":"Ridgway, H., Ntallis, C., Chasapis, C.T., Kelaidonis, K., Matsoukas, M.-T., Plotas, P., Apostolopoulos, V., Moore, G., Tsiodras, S., and Paraskevis, D. (2023). Molecular Epidemiology of SARS-CoV-2: The Dominant Role of Arginine in Mutations and Infectivity. Viruses, 15.","DOI":"10.3390\/v15020309"},{"key":"ref_310","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1080\/14728222.2024.2362675","article-title":"Novel Benzimidazole Angiotensin Receptor Blockers with Anti-SARS-CoV-2 Activity Equipotent to That of Nirmatrelvir: Computational and Enzymatic Studies","volume":"28","author":"Ridgway","year":"2024","journal-title":"Expert. Opin. Ther. Targets"},{"key":"ref_311","doi-asserted-by":"crossref","first-page":"3585","DOI":"10.1021\/jm950690v","article-title":"Synthesis and Contractile Activities of Cyclic Thrombin Receptor-Derived Peptide Analogues with a Phe-Leu-Leu-Arg Motif: Importance of the Phe\/Arg Relative Conformation and the Primary Amino Group for Activity","volume":"39","author":"Matsoukas","year":"1996","journal-title":"J. Med. Chem."},{"key":"ref_312","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1080\/10623320109051565","article-title":"Modulation of Angiogenesis and Progelatinase a by Thrombin Receptor Mimetics and Antagonists","volume":"8","author":"Maragoudakis","year":"2001","journal-title":"Endothelium"},{"key":"ref_313","doi-asserted-by":"crossref","first-page":"3338","DOI":"10.1021\/jm031080v","article-title":"Design and Synthesis of Novel Biologically Active Thrombin Receptor Non-Peptide Mimetics Based on the Pharmacophoric Cluster Phe\/Arg\/NH2 of the Ser42-Phe-Leu-Leu-Arg46 Motif Sequence: Platelet Aggregation and Relaxant Activities","volume":"47","author":"Alexopoulos","year":"2004","journal-title":"J. Med. Chem."},{"key":"ref_314","doi-asserted-by":"crossref","first-page":"1639","DOI":"10.1016\/S0968-0896(01)00059-1","article-title":"Synthesis and Study of a Cyclic Angiotensin II Antagonist Analogue Reveals the Role of \u03a0*\u2013\u03a0* Interactions in the C-Terminal Aromatic Residue for Agonist Activity and Its Structure Resemblance with AT1 Non-Peptide Antagonists","volume":"9","author":"Polevaya","year":"2001","journal-title":"Bioorganic Med. Chem."},{"key":"ref_315","doi-asserted-by":"crossref","first-page":"116870","DOI":"10.1016\/j.ejmech.2024.116870","article-title":"Tetrazoles: A Multi-Potent Motif in Drug Design","volume":"279","author":"Yuan","year":"2024","journal-title":"Eur. J. Med. Chem."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8819\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:43:24Z","timestamp":1760035404000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/26\/18\/8819"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9,10]]},"references-count":315,"journal-issue":{"issue":"18","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["ijms26188819"],"URL":"https:\/\/doi.org\/10.3390\/ijms26188819","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,9,10]]}}}